Project Grant R01AI202514
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $598,906 on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of respiratory viral infections in hospitalized children. The research examines how early-life respiratory tract infections contribute to asthma development by analyzing nasal transcriptomes in children hospitalized with bronchiolitis or asthma. The project team...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $806,740 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the mechanisms by which natural environmental agents from traditional Amish farms protect the lungs against rhinovirus infection and associated asthma development in children. The research investigates how early-life exposure to cow barn environments and barn-derived substances present...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $100,228 on December 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on microbe-induced immune alterations that protect against allergic airway eosinophilia. The research tests the hypothesis that inhalation exposure to Streptococcus pneumoniae confers protection against allergic airway eosinophilia—excessive eosinophil recruitment to...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $825,786 on July 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how diet-mediated gut microbiome interactions influence early-life susceptibility to respiratory infection and childhood asthma risk. The research project, titled "Determining Diet by Microbiome Interactions That Mitigate Early Life Susceptibility to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $236,660 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate IL-33-dependent and IL-33-independent pathways in allergic asthma. The project examines how IL-33 signaling drives type-2 inflammatory responses in allergic asthma and why blockade of IL-33 has produced mixed clinical trial results despite its position as an upstream therapeutic target. The...
- The National Institute of Allergy and Infectious Diseases awarded a $1.625 million Cooperative Agreement to The University of Chicago on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a nested case-control study of food allergy, atopic dermatitis, and wheezing illness in early childhood using cross-tissue multi-omic analysis. The recipient will characterize transcriptional and methylome signatures in blood cells and nasal mucosal cells collected...
- The National Institute of Allergy and Infectious Diseases awarded National Jewish Health $776,394 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate prenatal programming of immune cells in asthma, specifically how maternal exposure to diesel exhaust particles impairs embryonic growth and alters mast cell function to drive airway remodeling. The research uses a mouse model to establish mechanistic linkages between maternal environmental...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement totaling $564,548 to the Regents of the University of Michigan on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into how bone-marrow multipotent progenitors bearing the FcεRI receptor drive mast-cell–mediated allergic responses at mucosal sites. The project addresses the gap between current therapies that target downstream mast-cell...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $797,394 under Project Grant R01AI201440 on August 1, 2026, to define mechanistic pathways through which infant gut microbial metabolites affect immune responses to airway viral infection and aeroallergens, and to assess their impact on airway barrier integrity. Funding supports the Allergy and Infectious Diseases Research program (CFDA 93.855). The research builds on preliminary findings from the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $213,811 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop chimeric antigen receptor-engineered neutrophils as a therapeutic for Aspergillus fumigatus infection. The award funds research to engineer induced pluripotent stem cell-derived neutrophils armed with anti-Aspergillus CARs to overcome the limited efficacy of conventional antifungal agents...